MICONAZOLE 3 COMBINATION PACK bulk active fine chemical sources

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich	⤷ Get Started Free	M3512_SIGMA	⤷ Get Started Free
TCI (Tokyo Chemical Industry)	⤷ Get Started Free	M1769	⤷ Get Started Free
Molport	⤷ Get Started Free	MolPort-003-665-537	⤷ Get Started Free
Amadis Chemical	⤷ Get Started Free	A816380	⤷ Get Started Free
TimTec	⤷ Get Started Free	SBB057009	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 8, 2025

Introduction

The demand for bulk Active Pharmaceutical Ingredients (APIs) such as Miconazole in combination packs underscores the global emphasis on comprehensive antifungal treatment options. Miconazole, a broad-spectrum azole antifungal, is widely used in various formulations, especially in combination therapies designed to treat complex or localized fungal infections. Ensuring the supply chain integrity for Miconazole APIs involves sourcing from reputable manufacturers with stringent quality standards, regulatory compliance, and competitive pricing. This analysis explores key suppliers, sourcing considerations, and market dynamics relevant to pharmaceutical manufacturers and stakeholders involved in production and procurement.

Overview of Miconazole API

Miconazole is a potent antifungal agent used in creams, powders, sprays, and oral formulations. Its efficacy spans dermatophyte infections, candidiasis, and athlete's foot. The API's production requires rigorous synthesis processes, often involving imidazole derivatives. Given its critical role in combination packs, the API's quality, stability, and regulatory compliance are vital for effective product development and patient safety.

The specific mention of a "3 Combination Pack" indicates a formulation involving Miconazole with two other pharmacologically complementary agents, targeting multifaceted fungal conditions. This necessitates high-quality APIs, often procured in bulk for formulation efficiency and cost-effectiveness.

Key Global API Suppliers for Miconazole

1. Major Manufacturers and Contract Manufacturing Organizations (CMOs)

Zhejiang Chuangxin Pharmaceutical Co., Ltd. (China): A leading producer of antifungal APIs, Zhejiang Chuangxin supplies high-grade Miconazole API conforming to international standards, including USP and EP. The company's manufacturing facilities hold GMP certifications, making their APIs suitable for global markets [1].
Hetero Labs Limited (India): Known for robust API production with stringent quality controls, Hetero's Miconazole APIs are positioned for global export, supported by relevant regulatory filings. They also offer API contract manufacturing tailored to client specifications [2].
Synthesis Enterprises (India): Specializing in antifungal APIs, Synthesis Enterprises maintains impeccable quality standards, with supply capabilities that meet regulatory demands across multiple regions.
Tianjin Pharm. Co., Ltd. (China): A reputable GMP-certified manufacturer with a comprehensive API portfolio, including Miconazole. Tianjin Pharm emphasizes compliant production processes aligned with international standards.
Panacea Biotec (India): A significant player with a history of API manufacturing, Panacea Biotec offers Miconazole API suitable for large-scale production, adhering to strict quality metrics [3].

2. Established Multinational API Suppliers

Dr. Reddy’s Laboratories (India): A globally recognized pharmaceutical company, Dr. Reddy’s supplies high-quality APIs, including Miconazole, with extensive regulatory approvals and certifications across numerous countries [4].
Sun Pharmaceutical Industries Ltd. (India): As one of the world's largest pharmaceutical firms, Sun Pharma offers reliable Miconazole APIs to accommodate various formulation needs, including combination packs.
Evonik Industries (Germany): While primarily known for specialty chemicals, Evonik manufactures pharmaceutical excipients and APIs, including antifungal agents, with a focus on quality and innovation.

3. Contract Manufacturing and Custom Synthesis Providers

Several CMOs specializing in antifungal APIs can offer bespoke synthesis processes, ensuring a consistent supply chain for combination pack formulation:

Alsacia Pharmaceuticals (India): Offers custom synthesis services with GMP compliance, suitable for multiple APIs, including Miconazole.
Wuxi AppTec (China): A global contract service provider capable of large-volume API synthesis, quality control, and regulatory support.

Sourcing Considerations for Miconazole API

Regulatory Compliance and Quality Assurance

Suppliers should possess current Good Manufacturing Practice (GMP) certifications and comprehensive documentation, including Certificates of Analysis (CoA), stability reports, and regulatory approvals. Ensuring the API adheres to pharmacopeial standards such as USP, EP, or JP is imperative for global markets.

Pricing and Supply Stability

Market dynamics, geopolitical stability, and capacity constraints influence API pricing and availability. The Indian pharmaceutical industry remains a low-cost, high-quality source, while Chinese suppliers often provide competitive pricing but necessitate thorough regulatory vetting.

Lead Time and Logistics

Timely delivery is crucial for production planning. Working with suppliers offering logistical flexibility and reliable supply chains enhances manufacturing efficiency. Establishing long-term relationships can mitigate risks associated with shortages.

Intellectual Property and Licensing

For patented or proprietary formulations, ensuring licensing agreements with API suppliers can prevent infringement issues. Most generic APIs such as Miconazole are unpatented, simplifying procurement.

Market Trends and Future Outlook

The antifungal API market continues to evolve, driven by increasing fungal infections, expanding research, and the rise of combination therapies. The global API market for Miconazole is expected to grow at a CAGR of approximately 4% over the next five years, with a particular focus on Asia-Pacific for manufacturing.

Emerging manufacturers investing in quality improvement and sustainability practices may become significant competitors. Innovations in synthesis routes aimed at reducing costs and environmental impact could further influence supplier choices.

Conclusion

Global sources of Miconazole API form a robust supply network primarily anchored in India and China, supported by reputable chemical and pharmaceutical manufacturers with compliance standards aligned to international regulatory regimes. Selecting the right supplier involves balancing quality, cost, capacity, and regulatory adherence, with due diligence to verify certifications, stability, and delivery reliability.

An optimized sourcing strategy for a Miconazole 3 combination pack leverages these established suppliers, adheres to quality standards, and ensures supply continuity, thus supporting efficient production and market competitiveness.

Key Takeaways

Leading suppliers of Miconazole API are predominantly based in India and China, with notable players offering GMP-compliant, high-quality products suitable for combination pack manufacturing.
Strict adherence to regulatory standards (GMP, USP, EP) is critical in selecting API sources to ensure product safety and market approval.
Cost, supply stability, and logistic reliability are pivotal in establishing supplier relationships; long-term partnerships contribute to supply chain resilience.
Contract manufacturing organizations (CMOs) provide flexibility for custom synthesis, quality control, and regulatory support, facilitating tailored supply solutions.
Market growth in antifungal APIs aligns with rising fungal infections globally, making strategic sourcing essential for sustained competitive advantage.

FAQs

1. What factors should be prioritized when sourcing Miconazole API for commercial production?
Quality certifications (GMP compliance), regulatory approvals (USP, EP), consistent supply capacity, competitive pricing, and reliable logistics are critical factors.

2. Are Chinese and Indian API manufacturers equally reliable for Miconazole?
Both regions host reputable manufacturers adhering to international quality standards. Due diligence regarding certification, past compliance, and quality audits is advisable to determine reliability.

3. How does regulatory compliance impact API sourcing?
Regulatory compliance ensures the API meets quality, safety, and efficacy standards required for approval in target markets, reducing the risk of product rejection and legal issues.

4. Can API manufacturers customize production processes for specific combination packs?
Yes, contract manufacturing organizations can tailor synthesis processes, purity levels, and packaging to meet specific formulation needs.

5. What is the future outlook for Miconazole API supply and demand?
Demand is expected to grow steadily, driven by increasing fungal infections and expanding combination therapies. Manufacturers investing in quality and sustainable practices will likely maintain competitive advantages.

References

[1] Zhejiang Chuangxin Pharmaceutical Co., Ltd. Website.
[2] Hetero Labs Limited. Corporate Report, 2022.
[3] Panacea Biotec Annual Report, 2021.
[4] Dr. Reddy’s Laboratories Product Portfolio Details.

Bulk Pharmaceutical API Sources for MICONAZOLE 3 COMBINATION PACK